333 related articles for article (PubMed ID: 26704388)
21. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.
van Delft MF; Wei AH; Mason KD; Vandenberg CJ; Chen L; Czabotar PE; Willis SN; Scott CL; Day CL; Cory S; Adams JM; Roberts AW; Huang DC
Cancer Cell; 2006 Nov; 10(5):389-99. PubMed ID: 17097561
[TBL] [Abstract][Full Text] [Related]
22. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.
Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N
Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848
[TBL] [Abstract][Full Text] [Related]
23. Norcantharidin combined with ABT-737 for hepatocellular carcinoma: Therapeutic effects and molecular mechanisms.
Ren J; Li G; Zhao W; Lin L; Ye T
World J Gastroenterol; 2016 Apr; 22(15):3962-8. PubMed ID: 27099439
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of NANOG/NANOGP8 downregulates MCL-1 in colorectal cancer cells and enhances the therapeutic efficacy of BH3 mimetics.
Mattoo AR; Zhang J; Espinoza LA; Jessup JM
Clin Cancer Res; 2014 Nov; 20(21):5446-55. PubMed ID: 25208882
[TBL] [Abstract][Full Text] [Related]
25. Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1.
Zhang S; Li G; Ma X; Wang Y; Liu G; Feng L; Zhao Y; Zhang G; Wu Y; Ye X; Qin B; Lu J
Cell Signal; 2012 Sep; 24(9):1803-9. PubMed ID: 22609455
[TBL] [Abstract][Full Text] [Related]
26. Quantitative assessment of the sensitivity of dormant AML cells to the BAD mimetics ABT-199 and ABT-737.
Yu N; Seedhouse C; Russell N; Pallis M
Leuk Lymphoma; 2018 Oct; 59(10):2447-2453. PubMed ID: 29431553
[TBL] [Abstract][Full Text] [Related]
27. Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding.
Song T; Chai G; Liu Y; Yu X; Wang Z; Zhang Z
Br J Pharmacol; 2016 Feb; 173(3):471-83. PubMed ID: 26493374
[TBL] [Abstract][Full Text] [Related]
28. p53-dependent regulation of Mcl-1 contributes to synergistic cell death by ionizing radiation and the Bcl-2/Bcl-XL inhibitor ABT-737.
Tagscherer KE; Fassl A; Sinkovic T; Combs SE; Roth W
Apoptosis; 2012 Feb; 17(2):187-99. PubMed ID: 22002102
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1.
Luedtke DA; Su Y; Liu S; Edwards H; Wang Y; Lin H; Taub JW; Ge Y
J Cell Mol Med; 2018 Dec; 22(12):6099-6111. PubMed ID: 30596398
[TBL] [Abstract][Full Text] [Related]
30. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.
Kang MH; Wan Z; Kang YH; Sposto R; Reynolds CP
J Natl Cancer Inst; 2008 Apr; 100(8):580-95. PubMed ID: 18398104
[TBL] [Abstract][Full Text] [Related]
31. Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.
Tromp JM; Geest CR; Breij EC; Elias JA; van Laar J; Luijks DM; Kater AP; Beaumont T; van Oers MH; Eldering E
Clin Cancer Res; 2012 Jan; 18(2):487-98. PubMed ID: 22128299
[TBL] [Abstract][Full Text] [Related]
32. HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.
Yang H; Lee MH; Park I; Jeon H; Choi J; Seo S; Kim SW; Koh GY; Park KS; Lee DH
Cancer Lett; 2017 Dec; 411():19-26. PubMed ID: 28987383
[TBL] [Abstract][Full Text] [Related]
33. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.
Miller LA; Goldstein NB; Johannes WU; Walton CH; Fujita M; Norris DA; Shellman YG
J Invest Dermatol; 2009 Apr; 129(4):964-71. PubMed ID: 18987671
[TBL] [Abstract][Full Text] [Related]
34. Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway.
Shi YF; Liu L; He LL; Ye J; Lin ZJ; Yuan DL; Deng MM; Fang ZH; Carter BZ; Xu B
Cell Death Dis; 2020 Jul; 11(7):555. PubMed ID: 32699295
[TBL] [Abstract][Full Text] [Related]
35. Perifosine and ABT-737 synergistically inhibit lung cancer cells in vitro and in vivo.
Shen J; Xu L; Zhao Q
Biochem Biophys Res Commun; 2016 May; 473(4):1170-1176. PubMed ID: 27073162
[TBL] [Abstract][Full Text] [Related]
36. Cafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression.
Woo SM; Min KJ; Seo BR; Nam JO; Choi KS; Yoo YH; Kwon TK
Cell Death Dis; 2014 Nov; 5(11):e1514. PubMed ID: 25375379
[TBL] [Abstract][Full Text] [Related]
37. Dinaciclib, a Cyclin-Dependent Kinase Inhibitor Promotes Proteasomal Degradation of Mcl-1 and Enhances ABT-737-Mediated Cell Death in Malignant Human Glioma Cell Lines.
Jane EP; Premkumar DR; Cavaleri JM; Sutera PA; Rajasekar T; Pollack IF
J Pharmacol Exp Ther; 2016 Feb; 356(2):354-65. PubMed ID: 26585571
[TBL] [Abstract][Full Text] [Related]
38. Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells.
Pallis M; Burrows F; Ryan J; Grundy M; Seedhouse C; Abdul-Aziz A; Montero J; Letai A; Russell N
Oncotarget; 2017 Mar; 8(10):16220-16232. PubMed ID: 27092880
[TBL] [Abstract][Full Text] [Related]
39. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.
Pan R; Hogdal LJ; Benito JM; Bucci D; Han L; Borthakur G; Cortes J; DeAngelo DJ; Debose L; Mu H; Döhner H; Gaidzik VI; Galinsky I; Golfman LS; Haferlach T; Harutyunyan KG; Hu J; Leverson JD; Marcucci G; Müschen M; Newman R; Park E; Ruvolo PP; Ruvolo V; Ryan J; Schindela S; Zweidler-McKay P; Stone RM; Kantarjian H; Andreeff M; Konopleva M; Letai AG
Cancer Discov; 2014 Mar; 4(3):362-75. PubMed ID: 24346116
[TBL] [Abstract][Full Text] [Related]
40. Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.
He L; Torres-Lockhart K; Forster N; Ramakrishnan S; Greninger P; Garnett MJ; McDermott U; Rothenberg SM; Benes CH; Ellisen LW
Cancer Discov; 2013 Mar; 3(3):324-37. PubMed ID: 23274910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]